To view this protected post, enter the password below:
The U.S. National Science Foundation has announced the first-ever NSF Regional Innovation Engines (NSF Engines) program that is awarding 10 teams spanning 18 states and a subset of semifinalists and finalists invited to pursue NSF Engines Development Awards to further develop their partnerships and model for a future NSF Engines proposal. NSF Engines represent one of the single largest broad investments in place-based research and development in the nation’s history – uniquely placing science and technology leadership as the central driver for regional economic competitiveness. After the completion of the initial NSF Engines grant, the public and private sector stakeholders in the Richmond-Petersburg region, working together as the Alliance for Building Better Medicine, will serve as one of the invited regional partners for the NSF Engines Development Awards. Learn more
Activation Capital, the convener of the Alliance for Building Better Medicine, Activation Capital, secured $2.5M in seed funding from GO Virginia and others, to help launch a regional accelerator cluster that went on to become the Alliance for Building Better Medicine. The goal the GO Virginia grant is to help build a globally competitive pharmaceutical manufacturing and R&D industry in the Central Virginia region. The support from GO Virginia helped fast-track regional efforts to reshore and secure the production of essential medicines in the United States, lower their costs and ensure access to quality medicines in the U.S. and around the world. Alliance for Building Better Medicine are currently supporting the GO Virginia project to assist with scale-up in infrastructure, workforce development, and supply chain development. Learn more
The U.S. Department of Commerce’s Economic Development Administration (EDA) has awarded the public and private sector stakeholders in the Richmond-Petersburg region, working together as the Alliance for Building Better Medicine, with $52,942,702 as winners of the national Build Back Better Regional Challenge. As the marquee of the EDA’s American Rescue Plan, the Build Back Better Regional Challenge aims to boost economic pandemic recovery and rebuild American communities by strengthening dynamic high-tech regional industry clusters across the country, while embracing economic equity, creating well-paying jobs, meeting priority national interests and enhancing U.S. competitiveness globally. The large federal grant will be matched by $13,339,919 of funding from private and public organizations, for a total investment of $77,792,402. Learn more
Our alliance does not define itself by lines on a map, partisanship, or titles. We are an ecosystem without “ego.” Our lifesaving results are the true form of measurement for the impact we deliver to the world.
We are reimagining manufacturing processes, creating new methods, and co-developing novel pharmaceutical products. The core differentiator that sets our ecosystem apart is our alliance’s ability to rethink the entire process for creating essential medicines – from starting ingredients to medicine cabinet. We drive down costs and drive-up quality as a result of our collective efforts to create and leverage new technologies that bring only the highest-quality medicines, once in shortage, to market in record time.
We believe in radical collaboration and participation at all times. This shared commitment is what our alliance is built upon, and it can be measured by our ability to bring together the most innovative pharmaceutical leaders and unique public-private partnerships to define a new era of health and wellness and to restore U.S. global competitiveness.
Always building better medicine is fundamental to our success. Better means safer, affordable, and readily available. Better means having reliable access to medications once in chronic shortage. And it means creating medicine quickly and efficiently in a fashion that has the least impact on our planet as possible. As an alliance, we build better medicine through excellence in execution, our ability to attract ongoing public and private investment, our commitment to the communities we serve, and our ability to protect the pharmaceutical supply chain.
Accelerating our region, our country, and our planet forward at all times can be found at the heart of everything we do. We serve as a catalyst for a globally competitive pharmaceutical manufacturing and R&D industry that spans 17 cities and counties in our region, we form ongoing partnerships with economic development agencies and industry partners, we empower manufacturers to grow and to create opportunities for 21st-century workforce development, we commercialize our shared discoveries, and we always strive to inspire further invention and investment.
We are committed to co-investing and attracting outside investment. The impact created by our alliance is the direct result of co-investments from the federal government, state and local government, private sector, and other partners all working to grow through a sustainable, fiscally responsible model of collaboration.
The industry ecosystem we have created in the Commonwealth of Virginia gauges its success using four dimensions of performance: health, social, environmental, and financial impact. We are holistic – addressing multiple, interconnected priorities such as translational research that sparks engineering research, strengthening degree programs and our higher education network, creating opportunities for 21st-century workforce development in life science/advanced pharmaceutical manufacturing, creating higher-paying jobs, producing medicine using environmentally friendly methods, enhancing Virginia’s competitiveness across the globe, attracting other suppliers, improving health and wellness, and more.